2025 Agenda Walk-through with Grace
We know a PDF can't tell you everything about how our partnering meetings work. That's why we want Grace to personally walk you through the 2025 agenda. You'll see how our unique blend of targeted pharma matchmaking, carefully designed networking, and an enhanced partnering platform can truly set you apart from your competitors. Just give us 3 minutes, and we'll show you exactly what this meeting did.
Looking to invest, acquire, license, or partner?
From leveraging linker technology of ADCs to improve the uptake of radioligands, demonstrating the advantage of dual, immunostimulatory or small molecule degraders as more potent payloads, or increasing tissue penetration propensity through novel conjugates to achieve better intracellular exposure; pharma is continuing to prioritize earlier external ADC assets to augment their internal programs.
Why do ADC Companies Want to Collaborate with Pharma?
- Improving understanding of pharma’s targets of interest, to refine fit and differentiation within the market
- Validating and increasing pharma’s awareness around technology platform’s ability to work in the way intended, and advance more selectivity, less resistance, and better potency of ADCs
- Gaining access to non-dilute capital to increase the cash flow runway, and advancing clinical validation through shared resources and risk
What do Pharma Gain from In-Licensing or Research Collaborations with Biotech Advancing Disruptive ADC Science?
- Expanding targetable landscape and opportunity to be first-in-class by pursuing underexploited targets
- Optimizing payload release to reduce off-target effects or overcome challenges of resistance
- Increase tissue penetration propensity to achieve more significant internalization and intracellular exposure to payloads with novel conjugates
Who Is It For?
For Pharma
With representation from the key players, gather with other oncology large pharma innovation scouts and business development teams, looking to assess, qualify or understand infrastructure for due diligence on promising ADC or Radiopharmaceutical technologies, in scope and on strategy for external innovation.
For Biotech & Academics
Creating a platform for face-to-face networking with targeted decision makers hyper-relevant to ADC and radiopharmaceutical investment, acquisition, licensing, and partnership; understanding what’s on scope and in strategy for buyers initiating business-to-business deals.
For Investors
As ADCs and Radiopharmaceuticals continue to be the most exciting opportunity for investment, deal activity, and clinical progress in life sciences, capitalize on the world’s largest gathering of business decision makers in early development to identify strategic assets with promising returns.
The focused niche really increased the impact for us overall. Thanks for including us in the program.
Global Search & Evaluation Lead, Pharma Partnering, Roche
It was a great group of high-quality companies/people in the perfect setting.
Senior Director of Acquisitions & Licensing, J&J
I liked the format: the panel and icebreaker session was a great start and helped with the 1:1s with the companies. The companies knew what Sanofi was looking for and made the 30-minute meetings very efficient.
Senior Director, Business Development, Sanofi
Explore the 2025 Event Guide
- Scout novel payloads or new linker conjugation chemistry with click-release tumor specificity.
- Bring disruptive science in early development into in-house pipelines to stay ahead of the curve.
- Identify strategic assets with compelling data packages and gain market intelligence into big pharma interests.
- Ensure investments yield returns in the dynamic ADC space.
- Seek alignment with pharma to validate technologies, differentiate assets, and creatively partner to raise capital and de-risk future pipelines.
Attending Companies Included
Explore the 2025 Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join ADC Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.